학술논문
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings
Document Type
Article
Author
Hummel, H.-D.; Seggewiss-Bernhardt, R.; Chatterjee, M.; Kufer, P.; Stienen, S.; Grüllich, C.; Deschler-Baier, B.; Bargou, R.C.; Goebeler, M.-E.; Miller, K.; De Santis, M.; Loidl, W.; Dittrich, C.; Buck, A.; Lapa, C.; Thurner, A.; Wittemer-Rump, S.; Koca, G.; Boix, O.; Döcke, W.-D.; Finnern, R.; Kusi, H.; Ajavon-Hartmann, A.; Sayehli, C.M.; Polat, B.
Source
In: Immunotherapy . (Immunotherapy, February 2021, 13(2):125-141)
Subject
Language
English
ISSN
17507448
1750743X
1750743X